Cerus Corporation to Release Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023

Rhea-AI Summary

Cerus Corporation (NASDAQ: CERS) will release its fourth quarter and full year 2022 financial results on February 28, 2023, after market close. A conference call is scheduled for 4:30 PM ET that same day, where management will discuss the results and provide a business outlook. The live webcast can be accessed via the Investor Relations page on the Cerus website. A replay will be available approximately three hours post-call until March 14, 2023. Cerus is focused on ensuring the safety of the global blood supply, offering advanced technologies like the INTERCEPT Blood System.

Positive

• Cerus will release Q4 and full year 2022 results, indicating active financial engagement.
• The upcoming management call demonstrates transparency and commitment to investor communication.

Negative

• None.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.

A replay will be available on Cerus’ website and will be available approximately three hours after the call through March 14, 2023.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230215005164/en/

Joel Trujillo – Senior Director, Investor Relations

Cerus Corporation

925-288-6137

Source: Cerus Corporation

FAQ

When will Cerus Corporation announce its fourth quarter and full year 2022 financial results?

Cerus Corporation will announce its financial results on February 28, 2023, after the market closes.

What time is the Cerus Corporation conference call scheduled for?

The conference call is scheduled for 4:30 PM ET on February 28, 2023.

How can I access the Cerus Corporation conference call?

You can access the conference call via the Investor Relations page on the Cerus website.

Will there be a replay of the Cerus Corporation conference call?

Yes, a replay will be available approximately three hours after the call until March 14, 2023.